Clinical trial · Interventional
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT00144482CI-TRIAL-00001958completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Induced Anemia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| recombinant human erythropoietin | Drug | — | UNRESOLVED |
| recombinant human erythropoietin placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: recombinant human erythropoietin
- type
- PLACEBO_COMPARATOR
- label
- 2
- interventionNames
- Drug: recombinant human erythropoietin placebo
Primary outcomes (1)
- measure
- The increase in Hb concentration
- timeFrame
- week 8
Secondary outcomes (1)
- measure
- Changes in QOL scores
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients Exclusion Criteria: * a history of myocardial, cerebral or pulmonary infarction * severe hypertension beyond control by drugs
References
Publications (0)
Data not yet available
No reference posted for this study.